You just read:

Viking Therapeutics Announces Positive Top-Line Results from Phase 2 Study of VK2809 in Patients with Non-Alcoholic Fatty Liver Disease (NAFLD) and Elevated LDL-Cholesterol

News provided by

Viking Therapeutics, Inc.

Sep 18, 2018, 07:05 ET